21:18 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Castle Creek discontinues Phase II of epidermolysis bullosa compound

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) discontinued the Phase II DELIVERS trial evaluating topical 1% diacerein (AC-203, CCP-020) to treat epidermolysis bullosa simplex (EBS). According to ClinicalTrials.gov, an IDMC said the trial will not meet...
19:28 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

Castle Creek begins Phase II/III of topical diacerein to treat epidermolysis bullosa simplex

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) began the Phase II/III DELIVERS trial to evaluate topical 1% diacerein (AC-203, CCP-020) in about 80 patients ages ≥4 with epidermolysis bullosa simplex. The double-blind, international trial will test...
07:00 , Oct 3, 2016 |  BC Extra  |  Financial News

Rare disease play Castle Creek raises $48M

Specialty dermatology and ear, nose and throat company Castle Creek Pharmaceuticals LLC (Bedminster, N.J.) raised $48 million in a series A round from Fidelity. This quarter, the company expects to begin a pivotal Phase II/III...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 6-1 that Rejena from Lantibio did not demonstrate adequate safety and efficacy to treat signs and symptoms of dry eye disease. Rejena is a 0.18% sodium hyaluronate...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Clinical News

Vismed sodium hyaluronate opthalmic solution regulatory update

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on June 26 to discuss an NDA from Lantibio for Vismed to treat signs and symptoms of dry eye disease. Vismed is a 0.18% sodium hyaluronate...
08:00 , Jan 8, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Transplantation Graft rejection IL-1a; IL-1 receptor 1 (IL1R1; IL-1R1); IL-17 Studies in mice suggest that blocking IL-1a or IL-17 activity may...
07:00 , Sep 29, 2008 |  BioCentury  |  Product Development

Ophthalmic deals

Ophthalmic deals...
08:00 , Nov 12, 2007 |  BC Week In Review  |  Company News

Lantibio, TRB Chemedica, Alcon Laboratories Inc. deal

Lantibio and TRB granted Alcon exclusive U.S. rights to commercialize Vismed to treat dry eye syndrome. The aqueous solution of sodium hyaluronate is in Phase III testing for the indication. Lantibio plans to submit an...
07:00 , Oct 29, 2007 |  BC Week In Review  |  Company News

Gilead, TRB Chemedica infectious news

TRB filed for arbitration in the International Chamber of Commerce's International Court of Arbitration alleging that GILD's early termination of a 2003 distribution agreement was unlawful. That deal gave TRB exclusive rights to distribute GILD's...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Clinical News

Vismed: Phase III started

Lantibio began a double-blind, placebo-controlled, U.S. Phase III trial in 300 patients. The trial has an SPA from FDA. Last year, Lantibio licensed Vismed from TRB Chemedica, which markets the product in Europe. Lantibio Inc...